155 related articles for article (PubMed ID: 25367314)
1. Cost-effectiveness of renal denervation therapy for the treatment of resistant hypertension in The Netherlands.
Henry TL; De Brouwer BF; Van Keep MM; Blankestijn PJ; Bots ML; Koffijberg H
J Med Econ; 2015 Jan; 18(1):76-87. PubMed ID: 25367314
[TBL] [Abstract][Full Text] [Related]
2. Potential lifetime cost-effectiveness of catheter-based renal sympathetic denervation in patients with resistant hypertension.
Dorenkamp M; Bonaventura K; Leber AW; Boldt J; Sohns C; Boldt LH; Haverkamp W; Frei U; Roser M
Eur Heart J; 2013 Feb; 34(6):451-61. PubMed ID: 23091202
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of renal denervation therapy for the treatment of resistant hypertension in the UK.
Gladwell D; Henry T; Cook M; Akehurst R
Appl Health Econ Health Policy; 2014 Dec; 12(6):611-22. PubMed ID: 25086585
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.
Geisler BP; Egan BM; Cohen JT; Garner AM; Akehurst RL; Esler MD; Pietzsch JB
J Am Coll Cardiol; 2012 Oct; 60(14):1271-7. PubMed ID: 22981547
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Renal Denervation Therapy for Treatment-Resistant Hypertension: A Best Case Scenario.
Chowdhury EK; Reid CM; Zomer E; Kelly DJ; Liew D
Am J Hypertens; 2018 Sep; 31(10):1156-1163. PubMed ID: 30010694
[TBL] [Abstract][Full Text] [Related]
6. [Economic efficiency of renal denervation in patients with resistant hypertension: results of Markov modeling].
Kontsevaia AV; Suvorova EI; Khudiakov MB
Kardiologiia; 2014; 54(1):41-7. PubMed ID: 24881310
[TBL] [Abstract][Full Text] [Related]
7. Renal denervation in moderate treatment-resistant hypertension.
Ott C; Mahfoud F; Schmid A; Ditting T; Sobotka PA; Veelken R; Spies A; Ukena C; Laufs U; Uder M; Böhm M; Schmieder RE
J Am Coll Cardiol; 2013 Nov; 62(20):1880-6. PubMed ID: 23850901
[TBL] [Abstract][Full Text] [Related]
8. Renal denervation--hypes and hopes.
Lewek J; Kaczmarek K; Pokushalov E; Romanov A; Cygankiewicz I; Ptaszynski P
Cardiovasc Ther; 2015 Jun; 33(3):141-4. PubMed ID: 25786785
[TBL] [Abstract][Full Text] [Related]
9. Renal sympathetic denervation for resistant hypertension--an alternate view.
Das UN
Med Hypotheses; 2013 Dec; 81(6):1135-6. PubMed ID: 24225122
[TBL] [Abstract][Full Text] [Related]
10. Orthostatic function after renal sympathetic denervation in patients with resistant hypertension.
Lenski M; Mahfoud F; Razouk A; Ukena C; Lenski D; Barth C; Linz D; Laufs U; Kindermann I; Böhm M
Int J Cardiol; 2013 Nov; 169(6):418-24. PubMed ID: 24157238
[TBL] [Abstract][Full Text] [Related]
11. Ambulatory blood pressure changes after renal sympathetic denervation in patients with resistant hypertension.
Mahfoud F; Ukena C; Schmieder RE; Cremers B; Rump LC; Vonend O; Weil J; Schmidt M; Hoppe UC; Zeller T; Bauer A; Ott C; Blessing E; Sobotka PA; Krum H; Schlaich M; Esler M; Böhm M
Circulation; 2013 Jul; 128(2):132-40. PubMed ID: 23780578
[TBL] [Abstract][Full Text] [Related]
12. Renal denervation with cryoenergy as second-line option is effective in the treatment of resistant hypertension in non-responders to radiofrequency ablation.
Prochnau D; Heymel S; Otto S; Figulla HR; Surber R
EuroIntervention; 2014 Sep; 10(5):640-5. PubMed ID: 25256203
[TBL] [Abstract][Full Text] [Related]
13. Renal nerve ablation reduces augmentation index in patients with resistant hypertension.
Hering D; Lambert EA; Marusic P; Ika-Sari C; Walton AS; Krum H; Sobotka PA; Mahfoud F; Böhm M; Lambert GW; Esler MD; Schlaich MP
J Hypertens; 2013 Sep; 31(9):1893-900. PubMed ID: 23697964
[TBL] [Abstract][Full Text] [Related]
14. Limited destruction of renal nerves after catheter-based renal denervation: results of a human case study.
Vink EE; Goldschmeding R; Vink A; Weggemans C; Bleijs RL; Blankestijn PJ
Nephrol Dial Transplant; 2014 Aug; 29(8):1608-10. PubMed ID: 24875664
[TBL] [Abstract][Full Text] [Related]
15. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis.
Howard K; White S; Salkeld G; McDonald S; Craig JC; Chadban S; Cass A
Value Health; 2010; 13(2):196-208. PubMed ID: 19878493
[TBL] [Abstract][Full Text] [Related]
17. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
18. [Safety and short-term efficacy of renal sympathetic denervation in the treatment of resistant hypertension].
Jiang XJ; Liang T; Dong H; Peng M; Ma WJ; Guan T; Zhang HM; Bian J; Xu B; Gao RL
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(46):3265-8. PubMed ID: 23328511
[TBL] [Abstract][Full Text] [Related]
19. Improvement of albuminuria after renal denervation.
Ott C; Mahfoud F; Schmid A; Ditting T; Veelken R; Ewen S; Ukena C; Uder M; Böhm M; Schmieder RE
Int J Cardiol; 2014 May; 173(2):311-5. PubMed ID: 24681017
[TBL] [Abstract][Full Text] [Related]
20. Does renal artery supply indicate treatment success of renal denervation?
Schmid A; Ditting T; Sobotka PA; Veelken R; Schmieder RE; Uder M; Ott C
Cardiovasc Intervent Radiol; 2013 Aug; 36(4):987-91. PubMed ID: 23771326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
